Cellectis (Cellectis) Common Stock : $3.49 Mil (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Cellectis Common Stock?

Cellectis's quarterly common stock increased from Mar. 2023 ($3.49 Mil) to Jun. 2023 ($3.49 Mil) and increased from Jun. 2023 ($3.49 Mil) to Sep. 2023 ($3.49 Mil).

Cellectis's annual common stock increased from Dec. 2020 ($2.79 Mil) to Dec. 2021 ($2.95 Mil) and increased from Dec. 2021 ($2.95 Mil) to Dec. 2022 ($2.96 Mil).

Cellectis Common Stock Historical Data

The historical data trend for Cellectis's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Common Stock Chart

Cellectis Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Common Stock

Get a 7-Day Free Trial

2.77

2.79

2.95

2.96

Cellectis Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Common Stock	Get a 7-Day Free Trial															2.95	2.96	3.49	3.49	3.49

Cellectis Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Cellectis (Cellectis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

CMVLF:USA 0WA2:UK ALCLS:France ZVAA:Germany

Address

8, rue de la Croix Jarry, Paris, FRA, 75013

Website

https://www.cellectis.com

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.